活動名稱
【解題達人! We want you!】
活動說明
阿摩站上可謂臥虎藏龍，阿摩發出200萬顆鑽石號召達人們來解題!
針對一些題目可能有疑問但卻缺少討論，阿摩主動幫大家尋找最佳解!
懸賞試題多達20萬題，快看看是否有自己拿手的科目試題，一旦你的回應被選為最佳解，一題即可獲得10顆鑽石。
懸賞時間結束後，只要摩友觀看你的詳解，每次也會得到10顆鑽石喔!
關於鑽石
如何使用:
- ✔懸賞試題詳解
- ✔購買私人筆記
- ✔購買懸賞詳解
- ✔兌換VIP
(1000顆鑽石可換30天VIP) - ✔兌換現金
(50000顆鑽石可換NT$4,000)
如何獲得:
- ✔解答懸賞題目並被選為最佳解
- ✔撰寫私人筆記販售
- ✔撰寫詳解販售(必須超過10讚)
- ✔直接購買 (至站內商城選購)
** 所有鑽石收入，都會有10%的手續費用
近期考題
21. 有關幼兒園教保活動課程大綱立基於「仁」的教育觀。依據《論語》對於
「仁」的論述定義，下列哪種想法或說法較不屬於之？
(A)主張孩子沒有仁愛之心，光有禮制或音樂也沒意義。
(B)孩子心中有仁愛之心較不會有多餘的憂慮。
(C)如果是秉持仁愛，孩子也不必謙讓於老師。
(D)秉持仁愛之心的孩子，會正確地喜愛人而不應厭惡人。
(A)主張孩子沒有仁愛之心，光有禮制或音樂也沒意義。
(B)孩子心中有仁愛之心較不會有多餘的憂慮。
(C)如果是秉持仁愛，孩子也不必謙讓於老師。
(D)秉持仁愛之心的孩子，會正確地喜愛人而不應厭惡人。
【非選題】
三、某一擋水壩是以 10 年重現期距流量標準來做設計，試計算未來 5 年發
生溢壩洪水的機率。 （10 分）假設該擋水壩的年最大流量（單位為 CMS）
滿足對數皮爾遜第 III 型分布（log-Pearson type III distribution）
。流量取
以 10 為底數的對數後，平均值為 3，標準偏差為 0.3，偏態係數為 0.6。
試計算該擋水壩之設計流量。
（15 分）
【非選題】
【題組】 (a) Suppose that the RS is empty and the front end (decoder/register-renamer) will continue to supply two new instructions per clock cyclc. In cycle 0, the first two register-renamed instructions of this sequence appear in the RS. Assume it takes one clock cycle to dispatch any op in addition to the functional unit latencies. Then 9 clock cycles are required in the first iteration of this code sequence.
16. (5 points) Continuing from the last question, please answer which of the following statements is/are correct?
【題組】 (a) Suppose that the RS is empty and the front end (decoder/register-renamer) will continue to supply two new instructions per clock cyclc. In cycle 0, the first two register-renamed instructions of this sequence appear in the RS. Assume it takes one clock cycle to dispatch any op in addition to the functional unit latencies. Then 9 clock cycles are required in the first iteration of this code sequence.
【非選題】
【題組】(1-1)請說明本研究設計。(5%)
一、請詳閱下列這段敘述之後,依據其意回答問題:(本大題未使用中文回答,酌予扣分)(35%)
【摘錄自Chataway,DAngelisFConcPtal.Lancet Neurol. 2020 Mar; 19(3) :214-225.】
Background: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.
Methods: We did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 clinical neuroscience centres in the UK. We recruited patients (aged 25-65 years) with secondary progressive multiple sclerosis who were not on disease-modifying treatment and who had an Expanded Disability Status Scale (EDSS) score of 4 0-6:5. Participants were randomly assigned (1:1:1:1) at baseline, by a research nurse using a centralised web-based service, to receive twice-daily oral treatment of either amiloride 5 mg, fluoxetine 20 mg, riluzole 50 mg, or placebo for 96 weeks. The randomisation procedure included minimisation based on sex, age, EDSS score at randomisation, and trial site. Capsules were identical in appearance to achieve masking. Patients, investigators, and MRI readers were unaware of treatment allocation. The primary outcome measure was volumetric MRI percentage brain volume change (PBVC) from baseline to 96 weeks, analysed using multiple regression, adjusting for baseline normalised brain volume and minimisation criteria. The primary analysis was a complete-case analysis based on the intention-to-treat population (all patients with data at week 96). This trial is registered with Clinical Trials.gov, NCT0 1910259. Findings: Between Jan 29, 2015, and June 22, 2016, 445 patients were randomly allocated amiloride (n=111), fluoxetine (n=111), riluzole (n=111), or placebo (n=112). The primary analysis included 393 patients who were allocated amiloride (n=99), fluoxetine (n=96), riluzole (n=99), and placebo (n=99). No difference was noted between any active treatment and placebo in PBVC (amiloride vs placebo, 0.0% [95% CI -0ㆍ4 to 0ㆍ5; p-0.99]; fluoxetine vs placebo -0ㆍ1% [-0'5 to 0 3; p=0-86]; riluzole vs placebo -0ㆍ1% [-0ㆍ6 to 0:3; p-0.77). No emergent safety issues were reported. The incidence of serious adverse events was low and similar across study groups (ten [9%] patients in the amiloride group, seven [6%] in the fluoxetine group, 12 [11%] in the riluzole group, and 13 [12%] in the placebo group). The most common serious adverse events were infections and infestations. Three patients died during the study, from causes judged unrelated to active treatment; one patient assigned amiloride died from metastatic lung cancer, one patient assigned riluzole died from ischaemic heart disease and coronary artery thrombosis, and one patient assigned fluoxetine had a sudden death (primary cause) with multiple sclerosis and obesity listed as secondary causes.
【摘錄自Chataway,DAngelisFConcPtal.Lancet Neurol. 2020 Mar; 19(3) :214-225.】
Background: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.
Methods: We did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 clinical neuroscience centres in the UK. We recruited patients (aged 25-65 years) with secondary progressive multiple sclerosis who were not on disease-modifying treatment and who had an Expanded Disability Status Scale (EDSS) score of 4 0-6:5. Participants were randomly assigned (1:1:1:1) at baseline, by a research nurse using a centralised web-based service, to receive twice-daily oral treatment of either amiloride 5 mg, fluoxetine 20 mg, riluzole 50 mg, or placebo for 96 weeks. The randomisation procedure included minimisation based on sex, age, EDSS score at randomisation, and trial site. Capsules were identical in appearance to achieve masking. Patients, investigators, and MRI readers were unaware of treatment allocation. The primary outcome measure was volumetric MRI percentage brain volume change (PBVC) from baseline to 96 weeks, analysed using multiple regression, adjusting for baseline normalised brain volume and minimisation criteria. The primary analysis was a complete-case analysis based on the intention-to-treat population (all patients with data at week 96). This trial is registered with Clinical Trials.gov, NCT0 1910259. Findings: Between Jan 29, 2015, and June 22, 2016, 445 patients were randomly allocated amiloride (n=111), fluoxetine (n=111), riluzole (n=111), or placebo (n=112). The primary analysis included 393 patients who were allocated amiloride (n=99), fluoxetine (n=96), riluzole (n=99), and placebo (n=99). No difference was noted between any active treatment and placebo in PBVC (amiloride vs placebo, 0.0% [95% CI -0ㆍ4 to 0ㆍ5; p-0.99]; fluoxetine vs placebo -0ㆍ1% [-0'5 to 0 3; p=0-86]; riluzole vs placebo -0ㆍ1% [-0ㆍ6 to 0:3; p-0.77). No emergent safety issues were reported. The incidence of serious adverse events was low and similar across study groups (ten [9%] patients in the amiloride group, seven [6%] in the fluoxetine group, 12 [11%] in the riluzole group, and 13 [12%] in the placebo group). The most common serious adverse events were infections and infestations. Three patients died during the study, from causes judged unrelated to active treatment; one patient assigned amiloride died from metastatic lung cancer, one patient assigned riluzole died from ischaemic heart disease and coronary artery thrombosis, and one patient assigned fluoxetine had a sudden death (primary cause) with multiple sclerosis and obesity listed as secondary causes.
【題組】(1-1)請說明本研究設計。(5%)